VCYT Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

59.235

Open

58.150

VWAP

56.95

Vol

1.14M

Mkt Cap

4.48B

Low

55.460

Amount

64.72M

EV/EBITDA(TTM)

35.05

Total Shares

79.79M

4.19B

EV/OCF(TTM)

25.21

P/S(TTM)

8.61

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Events Timeline

(ET)

2026-06-01

07:40:00

Veracyte Launches Prosigna Breast Recurrence Risk Test

2026-05-31 (ET)

2026-05-31

09:40:00

Veracyte Enzamet Trial Results Show Genomic Test Guides Treatment

2026-05-15 (ET)

2026-05-15

09:10:00

Veracyte's TrueMRD Monitoring Test Receives CMS Coverage

2026-05-05 (ET)

2026-05-05

17:10:00

Veracyte Reports Q1 Revenue of $139.1M

2026-05-05

17:10:00

Company Raises 2026 Total Revenue Guidance to $582M to $592M

News

5.0

07-04Fool

Veracyte Executive Sells Shares for Over $1.09 Million

5.0

07-04NASDAQ.COM

Veracyte's Chief Accounting Officer Sells Shares

5.0

06-27NASDAQ.COM

Veracyte Director Sells 3,729 Shares in Routine Transaction

5.0

06-27Fool

Analysis of Veracyte Executive Stock Sale

4.5

06-17Yahoo Finance

Dow Jones Hits Record High, AI Stocks Decline

8.5

06-01Newsfilter

Veracyte Launches Prosigna Breast Cancer Risk Test

5 Analyst Rating

Wall Street analysts forecast VCYT stock price to rise

3 Buy

1 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

43.00

Averages

46.25

High

50.00

Current: 0.000

Low

43.00

Averages

46.25

High

50.00

Guggenheim

Subbu Nambi

Buy

maintain

$45 -> $65

AI Analysis

2026-06-29

Reason

Guggenheim

Subbu Nambi

Price Target

$45 -> $65

AI Analysis

2026-06-29

maintain

Buy

Reason

Guggenheim analyst Subbu Nambi raised the firm's price target on Veracyte to $65 from $45 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies in its diagnostics and life sciences tools coverage after meetings with management teams.

Wolfe Research

NULL

Outperform

initiated

$50 -> $55

2026-06-01

Reason

Wolfe Research

Price Target

$50 -> $55

2026-06-01

initiated

NULL

Outperform

Reason

Wolfe Research assumed coverage of Veracyte with an Outperform rating and price target of $55, up from $50. The company's testing assets, Afirma and Decipher, bring "rare comfort in reimbursement stability and established test value," the analyst tells investors in a research note. Wolfe sees potential upside for Veracyte from molecular residual disease or Prosigna,

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VCYT

Unlock Now

Valuation Metrics

The current forward P/E ratio for Veracyte Inc (VCYT.O) is 33.22, compared to its 5-year average forward P/E of -5.81. For a more detailed relative valuation and DCF analysis to assess Veracyte Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.81

Current PE

33.22

Overvalued PE

1307.74

Undervalued PE

-1319.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-44.31

Current EV/EBITDA

34.42

Overvalued EV/EBITDA

106.22

Undervalued EV/EBITDA

-194.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.87

Current PS

7.08

Overvalued PS

8.34

Undervalued PS

3.39

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what is good stock to day trade today

Intellectia · 36 candidates

Price: $5.00 - $80.00Price Change Pct: $3.00 - $15.00Relative Vol: >= 1.50Beta: HighRiskList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

BSY

Bentley Systems Inc

11.64B

FIGS

Figs Inc

2.05B

MGNI

Magnite Inc

1.95B

CRSP

CRISPR Therapeutics AG

5.93B

WWW

Wolverine World Wide Inc

1.64B

ARHS

Arhaus Inc

1.31B

Whales Holding VCYT

ARK Investment Management LLC

Deerfield Management Company, L.P.

ArrowMark Colorado Holdings, LLC

AMI Asset Management Corp

Trading Trends

People Also Watch

Frequently Asked Questions

What is Veracyte Inc (VCYT) stock price today?

The current price of VCYT is 56.16 USD — it has decreased -3.16

What is Veracyte Inc (VCYT)'s business?

What is the price predicton of VCYT Stock?

Wall Street analysts forecast VCYT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is46.25 USD with a low forecast of 43.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.